6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases

Help me get ahead. $200/year

Newsletters

CMS to pay for ADHD DTx. More PFS notes. Two FDA De Novos.

11.07.25

6 min. Read

Pricing for Sword Health, Hinge Health, Joint Academy in the UK.

10.31.25

7 min. Read

Spring, Slingshot AI, Click and others write FDA about GenAI. Big Health board departs.

10.24.25

7 min. Read

Cigna clarifies new non-coverage policy for PDTs. Bevel $10M. FDA GenAI comments.

10.17.25

5 min. Read

Revisiting E&O scoops, pricing intel, revenue finds

10.10.25

7 min. Read

Big Health’s 2024 revenue shrinks. 2025: Runway worries.

9.26.25

5 min. Read

Kavira Health pricing. What did Swing Therapeutics buy? PFS Comments.

9.18.25

7 min. Read

Cerebral’s $25M M&A. Amazon-Fay. Oshi growth numbers.

9.12.25

4 min. Read

Letters to CMS: DMHT codes, MDPP pricing, more. Plus: Unannounced funding.

9.05.25

6 min. Read

Pricing updates: Teladoc, Maven, Garner, Kaia and more

8.29.25

4 min. Read

Scoop: Amwell in talks to buy Omada

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.